Ahn M-J et al. An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09). ASCO 2018;Abstract 9050.

Hamilton EP et al. Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies. ASCO 2020;Abstract TPS3665.

Le X et al. Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients — A phase 2 study. AACR 2020;Abstract CT081.

Liu SV et al. First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. ESMO 2020;Abstract LBA61.

Park K et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). ASCO 2020;Abstract 9512.

Piotrowska Z et al. ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. ASCO 2020;Abstract 9513.

Piotrowska Z et al. Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20). ESMO 2020;Abstract 1345P.

Riely G et al. Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins). ESMO 2020;Abstract 1261MO.

Socinski M et al. ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. ESMO 2020;Abstract LBA60.

Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019;4:5. Abstract